F Baghai1, F Yazdani2, A Etebarian3, A Garajei4, A Skalova5. 1. Department of Oral and Maxillofacial Pathology, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran. 2. Department of Pathology, Amir Alam Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 3. Department of Oral and Maxillofacial Pathology, School of Dentistry, Alborz University of Medical Sciences, Karaj, Iran. Electronic address: arghavan.etebarian@gmail.com. 4. Department of Oral and Maxillofacial Surgery, School of Dentistry, and Department of Head and Neck Surgical Oncology and Reconstructive Surgery, The Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 5. Department of Pathology, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
Abstract
BACKGROUND: Mammary analogue secretory carcinoma (MASC) is a newly recognized salivary gland tumor that harbors a characteristic balanced chromosomal translocation t (12; 15) (p13; q25) resulting in an ETV6-NTRK3 fusion gene. METHODS: Retrospective study of 111 salivary gland carcinomas revealed 37 cases with secretory features and growth patterns resembling secretory carcinoma of breast. These 37 cases were originally diagnosed as acinic cell carcinoma, adenocarcinoma not otherwise specified and cystadenocarcinoma. Positive immunostaining for S-100 protein and mammaglobin, followed by detection of ETV6 gene rearrangement by FISH and/or ETV6-NTRK3 fusion transcript by RT-PCR were used to identify MASCs. RESULTS: In the cohort of 37 salivary carcinomas with secretory features we have identified 10 cases of MASC. All 10 MASCs were positive for mammaglobin, S-100 protein and SOX10, while staining for DOG1 and p63 protein were mostly absent. In 7/10 cases, both FISH and RT-PCR were positive while three remaining cases showed break of ETV6 gene by FISH analysis and the RT-PCR was negative. Clinical follow-up data were obtained in 6 out of 10 patients with MASC. In 3 patients cervical lymph node metastases developed, one patient with high grade transformed MASC died with multiple distant bone metastases, and local recurrence was observed in three patients. CONCLUSION: Our clinicopathological data are in keeping with previous studies; in most cases, MASC is a low-grade malignancy with overall favorable prognosis. In rare cases, however, MASC with high-grade transformation may behave aggressively, and these patients could benefit from targeted biological treatment using tyrosine kinase inhibitors.
BACKGROUND: Mammary analogue secretory carcinoma (MASC) is a newly recognized salivary gland tumor that harbors a characteristic balanced chromosomal translocation t (12; 15) (p13; q25) resulting in an ETV6-NTRK3 fusion gene. METHODS: Retrospective study of 111 salivary gland carcinomas revealed 37 cases with secretory features and growth patterns resembling secretory carcinoma of breast. These 37 cases were originally diagnosed as acinic cell carcinoma, adenocarcinoma not otherwise specified and cystadenocarcinoma. Positive immunostaining for S-100 protein and mammaglobin, followed by detection of ETV6 gene rearrangement by FISH and/or ETV6-NTRK3 fusion transcript by RT-PCR were used to identify MASCs. RESULTS: In the cohort of 37 salivary carcinomas with secretory features we have identified 10 cases of MASC. All 10 MASCs were positive for mammaglobin, S-100 protein and SOX10, while staining for DOG1 and p63 protein were mostly absent. In 7/10 cases, both FISH and RT-PCR were positive while three remaining cases showed break of ETV6 gene by FISH analysis and the RT-PCR was negative. Clinical follow-up data were obtained in 6 out of 10 patients with MASC. In 3 patients cervical lymph node metastases developed, one patient with high grade transformed MASC died with multiple distant bone metastases, and local recurrence was observed in three patients. CONCLUSION: Our clinicopathological data are in keeping with previous studies; in most cases, MASC is a low-grade malignancy with overall favorable prognosis. In rare cases, however, MASC with high-grade transformation may behave aggressively, and these patients could benefit from targeted biological treatment using tyrosine kinase inhibitors.
Authors: Ezra Y Rosen; Debra A Goldman; Jaclyn F Hechtman; Ryma Benayed; Alison M Schram; Emiliano Cocco; Sophie Shifman; Yixiao Gong; Ritika Kundra; James P Solomon; Alberto Bardelli; Maurizio Scaltriti; Alexander Drilon; Alexia Iasonos; Barry S Taylor; David M Hyman Journal: Clin Cancer Res Date: 2019-12-23 Impact factor: 12.531
Authors: Bin Xu; Kartik Viswanathan; Kavita Umrau; Thair A D Al-Ameri; Snjezana Dogan; Kelly Magliocca; Ronald A Ghossein; Nicole A Cipriani; Nora Katabi Journal: Histopathology Date: 2022-09-05 Impact factor: 7.778
Authors: David Forner; Martin Bullock; Daniel Manders; Timothy Wallace; Christopher J Chin; Liane B Johnson; Matthew H Rigby; Jonathan R Trites; Mark S Taylor; Robert D Hart Journal: J Otolaryngol Head Neck Surg Date: 2018-11-16